In term of breast cancer, up to 30% of those diagnosed as in situ breast cancer exhibit tumour dormancy with metastasis-free [7], which will make these individuals particularly vulnerable to any adverse activities of IFNγ-related breast cancer management. The gene discussed is IFNG; the disease is breast carcinoma.